Xtant Medical Holdings, Inc. · AMEX:XTNT
Xtant Medical — Investor Presentation (May 2021)
18 slides from Xtant Medical's investor presentation, May 20, 2021
Slide 1: Investor Presentation
\4 xX TANT MEDICA www.xtantmedical.com Investor Presentation May 20, 2021
Slide 2: Disclosure Statements
iw” DISCLOSURE STATEMENTS Cautionary Statement Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements that are predictive in nature, that dep
Slide 3: Disclosure Statements: Non-GAAP Financial Measures
Na DISCLOSURE STATEMENTS Non-GAAP Financial Measures To supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles, the company uses certain non-GAAP financial measures in this presentation, such as Adjusted EBITDA. The Compan
Slide 4: Summary: Xtant Medical
SUMMARY: XTANT MEDICAL Re-birth of a Leading Spine Brand — Exceptional quality biologics — Very strong niche fixation products Platform for Growth — Exceptional Market Access with contracts and nationwide distribution — Updated bioproduction capabilities Financially Sound — Debt conversion with a cl
Slide 5: Experienced Senior Leadership Team
Na EXPERIENCED SENIOR LEADERSHIP TEAM SEAN BROWNE KEVIN BRANDT GREG JENSEN PRESIDENT, CHIEF ‘CHIEF COMMERICAL CHIEF FINANCIAL OFFICER EXECUTIVE OFFICER OFFICER FY ” = American Solutions for = Baxter = Zimmer Business = McKesson * Stryker = WIC Industries = Integra LifeSciences = RT = EnviroStaff = C
Slide 6: Evolution Now Has Xtant
EVOLUTION NOW HAS XTANT POISED FOR GROWTH Xtant Medical unites exceptional biologics with intuitive fixation design to provide surgical solutions that advance regenerative medicine. ~~, . Da] xXspine. ) §Bacterwn 2003 ( X-spine Systems ied is founded Orthobiologics is founded @) OXTANT 2015 Bacterin
Slide 7: Global Spine and Orthobiologic Market
GLOBAL SPINE AND ORTHOBIOLOGIC MARKET, Total WW market: $9.7B $7.58 $243 = 7 Source: Markets and Markets & Data US Market Report Suite for Orthopedic Biomaterials XTANT
Slide 8: US Orthobiologic Market
8 US ORTHOBIOLOGIC MARKET Opportunity to leverage #4 U.S. market share position in demineralized bone matrix (DBM) via strong distribution and GPO/IDN relationships and expansion into adjacent markets. oe cat $485M Allogratt $163M Alogar $51IM sctecu: $583M Growth $672M Factor Source: Data US Market
Slide 9: Biologics Safety & Efficacy
BIOLOGICS SAFETY & EFFICACY Strong clinical evidence that points toa very high safety and effectiveness profile for DBM * Autograft Demineralized Bone Matrix (DBM) Growing evidence undermining the $511M Stem Cell Market (e.g., HCA will not reimburse, SeaSpine study) Synthetics Safety $500M market op
Slide 10: Product Portfolio: Biologics Innovation
10 PRODUCT PORTFOLIO: BIOLOGICS INNOVATIO iil d ¢ 2 _ a ae «CG Ss I & 4 = it T = ‘TLIFIPLIF/ALIF LUMBAR FUSION i) pi wLLe0 GRAFTS DEMINERALIZED BONE MATRIX ee TRADITIONAL GRAFTS. AMNIOTIC TISSUE SACROILIAC FUSION = FIXATION BIOLOGICS XTANT
Slide 11: Committed to Clinical Evidence: Publications
COMMITTED TO CLINICAL EVIDENCE: PUBLICATIONS Propuct STUDYDESIGN OsteoSponge Retrospective case series Expert Summary, Pre-Clinical, _Oxteosponge especie Cae Sues Osteosponge Prospective Cas Series “‘Ostecsponge Revospectve, MutCenter “ osteosponge Revospectve Cose Sees “‘OstecSponge Rewospectve Cas
Slide 12: Growth Strategy Pillars
GROWTH STRATEGY PILLARS XTANT MEDICAL GROWTH STRATEGY Expand Leverage M&A Activity Distribution Adjacent Network Markets Drive new Sell deeper and Utilize current Acquire best in innovations and broader —- become portfolio to class technologies Distributor a strong national penetrate to enhance curr
Slide 13: Organic Growth Initiative: New Product Flow
B ORGANIC GROWTH INITIATIVE: NEW PRODUC FLOW = Introduce 4-6 new products per year = Roll-out next generation of demineralized bone matrix = Expand fixation product set 2021 @ MarrowCellutions + OsteoSponge BMA Delivery System 9 ——— @ Osteo 100 & ‘Moldable Allograft @ Growth Factor Powder @ OsteoMix
Slide 14: Expand Distribution Network Initiative
4 EXPAND DISTRIBUTION NETWORK INITIATIVE CONTRACTUAL ACCESS: + All National GPO Contracts * 385 IDN Contracts * DOD/VA Access Plan to Increase Distributor Revenue by 10% Annually Open Distribution Channel 288 current distributors $224K revenue per distributor annually — target to grow to $300K per d
Slide 15: 2020 Sales Coverage
2020 SALES COVERAGE Significant opportunities to expand our distribution footprint in some of the most populated regions of the country Northeast, Midwest, and Mid- Atlantic *Blue states have Independent Agents of over $100K/YR, while Gra 15 states have agents below $100K/YR WxtaAnT
Slide 16: Plan to Grow Adjacent Markets
PLAN TO GROW ADJACENT 82% of Xtant’s Biologics Revenue is Focused on Spine Procedures 3Demin® ‘QsteoSponge” Cancellous DBM Cortical DBM Fibers DBM Putty OsteoVive® ‘Matriform® Viable Cell Allograft ‘Synthetic: Bone Graft 16 Na MARKETS é 18% of Xtant’s Biologics Revenue is Non-Spine Sales Potential B
Slide 17: Leverage M&A: Bring scale
7 Bring scale Fill product/ capabilities gaps Bring differentiated products Leverageable commercial assets Increased market access "Sharehok de Value
Slide 18: Investment Opportunity
Xtant Medical Holdings — Investor Presentation (May 2021) on 6ix